Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2653 - A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Filippo de Marinis


Annals of Oncology (2019) 30 (suppl_5): v591-v601. 10.1093/annonc/mdz259


F. de Marinis1, H. Tu2, K.K. Laktionov3, J. Feng4, A. Poltoratskiy5, J. Zhao6, I. Egorova7, E. Tan8, M. Gottfried9, V. Lee10, D.M. Kowalski11, C. Yang12, B.J. Srinivasa13, A. Passaro1, L. Clementi14, W. Tang15, D.C. Huang16, A. Cseh17, C. Zhou18, Y. Wu2

Author affiliations

  • 1 Department Of Thoracic Oncology, European Institute of Oncology IRCCS, 20141 - Milan/IT
  • 2 Guangdong Lung Cancer Institute, Guangdong Provincial Peoples Hospital and Guangdong Academy of Medical Sciences, Guangzhou/CN
  • 3 Carcinogenesis Institute Of N.n Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, 119991 - Moscow/RU
  • 4 Department Of Chemotherapy, Jiangsu Cancer Hospital & Jiangsu Institute Of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing/CN
  • 5 Department Of Preclinical And Clinical Trials, Petrov Research Institute of Oncology, St Petersburg/RU
  • 6 Key Laboratory Of Carcinogenesis And Translational Research (ministry Of Education/beijing), Department 1 of Thoracic Oncology Medicine, Peking University Cancer Hospital & Institute, Beijing/CN
  • 7 Thoracic Department, Clinical Oncology Dispensary, St Petersburg/RU
  • 8 Department Of Medical Oncology, National Cancer Centre, Singapore/SG
  • 9 Department Of Oncology, Tel Aviv University, Tel Aviv/IL
  • 10 Department Of Clinical Oncology, Queen Mary Hospital, The University of Hong Kong, Hong Kong/CN
  • 11 Department Of Lung Cancer And Thoracic Oncology, , Oncology Centre and Institute, 02-781 - Warsaw/PL
  • 12 Department Of Thoracic Medicine, Chang Gung Memorial Hospital, Guishan, Taoyuan/TW
  • 13 Department Of Medical Oncology, HCG Hospital, Bangalore/IN
  • 14 Clinical Operations, Boehringer Ingelheim Italia S.p.A., Milan/IT
  • 15 Statistics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield/US
  • 16 Department Of Medical Affairs, Boehringer Ingelheim Taiwan Limited, Taipei/TW
  • 17 Department Of Medical Affairs, Boehringer Ingelheim RCV GmbH & Co. KG, Vienna/AT
  • 18 Department Of Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2653


First-line afatinib significantly improved progression-free survival (PFS) in pts with EGFRm+ NSCLC compared with chemotherapy in LUX-Lung (LL) 3 and 6, and with gefitinib in LL7. However, in clinical practice, some EGFRm+ pts still receive chemotherapy as a first-line therapy. We report a combined analysis of data from two large, prospective, open-label, single-arm Phase IIIb studies of afatinib in pts with EGFR TKI-naïve NSCLC treated in a setting similar to real-world practice.


EGFR TKI-naïve pts with locally advanced/metastatic EGFRm+ NSCLC received 40 mg/day afatinib until progressive disease or lack of tolerability. Dose reduction to minimum 20 mg/day was permitted. Pts were enrolled across 8 European countries, Russia, Israel and Australia (study 1), and China, Hong Kong, India, Singapore and Taiwan (study 2). Time to symptomatic progression (TTSP), PFS, objective response and safety were analysed using interim (study 1; data cut-off 30 April 2018) and final (study 2; data cut-off 6 July 2018) data.


A total of 1020 pts were treated: female: 59%; Asian/White: 54%/46%; median age: 61 years; ECOG PS 0/1/2: 26%/69%/5%; common/uncommon EGFR mutations: 82%/18%; treatment line 1/2/≥3: 69%/23%/8%; brain metastases: 18%. Median TTSP was 14.6 months (95% CI: 13.8–15.8); median PFS was 12.9 months (95% CI: 11.6–13.7). Objective response (OR) rate was 52.7%; median duration of OR was 12.9 months (95% CI: 11.7–13.8). Adverse events (AEs; any grade/grade ≥3) occurred in 1012/556 pts (99.2%/54.5%). Drug-related AEs (DRAEs; any grade/grade ≥3) occurred in 990/361 pts (97.1%/35.4%); most frequently (grade ≥3) diarrhoea (13.3%) and rash (9.2%). DRAEs leading to treatment discontinuation were reported in 54 pts (5.3%). AEs leading to dose reduction occurred in 412 patients (40.4%). Serious AEs occurred in 366 pts (35.9%).


In this combined analysis, safety data for afatinib were consistent with results from LL3, 6 and 7. Efficacy data were encouraging, with a median TTSP of 14.6 months. This analysis, which includes pts treated in later lines, and pts with ECOG PS 2, brain metastases, or uncommon mutations, suggests that afatinib has clinical benefit for pts in the real-world clinical setting.

Clinical trial identification

NCT01853826 and NCT01953913.

Editorial acknowledgement

Beth de Klerk, of GeoMed, an Ashfield company, part of UDG Healthcare plc.; supported financially by Boehringer Ingelheim.

Legal entity responsible for the study

Boehringer Ingelheim.


Boehringer Ingelheim.


F. de Marinis: Honoraria (self), Advisory / Consultancy: Roche; Advisory / Consultancy: Takeda; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (institution), Research grant / Funding (self): Merck Sharp and Dohme; Research grant / Funding (self): Boehringer Ingelheim. A. Poltoratskiy: Advisory / Consultancy, Speaker Bureau / Expert testimony: GCP.center Russia. V. Lee: Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Eli Lilly; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Merck Sharp and Dohme. D.M. Kowalski: Advisory / Consultancy: Boehringer Ingelheim. A. Passaro: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Merck Sharp and Dohme; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Roche; Advisory / Consultancy: Dako. L. Clementi: Full / Part-time employment: Boehringer Ingelheim Italia SpA. W. Tang: Full / Part-time employment: Boehringer Ingelheim. D.C. Huang: Full / Part-time employment: Boehringer Ingelheim (Taiwan Limited). A. Cseh: Full / Part-time employment: Boehringer Ingelheim; Shareholder / Stockholder / Stock options, Husband: Mylan. C. Zhou: Honoraria (self): Boehringer Ingelheim; Honoraria (self): Roche; Honoraria (self): Sanofi; Honoraria (self): Hengrui; Honoraria (self): Qilu; Honoraria (self): Merck Sharp and Dohme. Y. Wu: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Roche; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Full / Part-time employment: Guangdong Provincial People’s Hospital, China; Honoraria (self): Eli Lilly; Honoraria (self): Pfizer; Honoraria (self), Research grant / Funding (self): Boehringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.